Wedbush is reiterating its Outperform rating on shares of ABIOMED (NASDAQ: ABMD) and is raising its price target from $16 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE